Table
of Contents
|
|
|
SECTION 1 |
THE CONCEPTUAL FRAMEWORK OF PHARMACOLOGY |
|
1 |
Introduction to Pharmacology |
3 |
|
Introduction |
4 |
|
Drug Sources |
4 |
|
Drug Classifications and Prototypes |
4 |
|
Drug Names |
4 |
|
Drug Marketing |
5 |
|
Pharmacoeconomics |
5 |
|
Access to Drugs |
5 |
|
Drug Approval Processes: Food and
Drug Administration |
7 |
|
Safety in Drug Administration |
9 |
|
Sources of Drug Information |
13 |
|
Strategies for Studying Pharmacology |
13 |
2 |
Basic Concepts and Processes |
16 |
|
Introduction |
17 |
|
Cellular Physiology |
17 |
|
Drug Transport Through Cell Membranes |
18 |
|
Pharmacokinetics |
18 |
|
Pharmacodynamics |
23 |
|
Variables that Affect Drug Actions |
23 |
|
Adverse Effects of Drugs |
28 |
|
Toxicology: Drug Overdose |
30 |
3 |
Medication Administration and the Nursing Process of
Drug Therapy |
35 |
|
General Principles of Accurate Drug Administration |
36 |
|
Legal Responsibilities |
37 |
|
Medication Errors and their
Prevention |
37 |
|
Medication Orders |
43 |
|
Drug Preparations and Dosage Forms |
44 |
|
Calculating Drug Dosages |
46 |
|
Routes of Administration |
47 |
|
Nursing Process in Drug Therapy |
53 |
|
Integrating Evidence-Based Practice
with the
Nursing Process |
60 |
|
Herbal and Dietary Supplements |
60 |
SECTION 2 |
DRUG THERAPY THROUGHOUT THE LIFESPAN |
|
4 |
Pharmacology and the Care of the Infant and Pediatric
Patient |
69 |
|
Introduction |
70 |
|
Drug Safety in Pediatrics |
70 |
|
Pharmacodynamics in Pediatrics |
71 |
|
Pharmacokinetics in Pediatrics |
71 |
|
Medication Administration in
Pediatrics |
72 |
5 |
Pharmacology and the Care of the Adult and Geriatric
Patient |
75 |
|
Introduction |
76 |
|
Pharmacodynamics in Older Adults |
76 |
|
Pharmacokinetics in Older Adults |
77 |
|
Medication Adherence and Aging |
78 |
|
The Nursing Process |
79 |
6 |
Pharmacology and the Pregnant or Lactating Woman |
82 |
|
Introduction |
83 |
|
Drug Therapy for Infertility |
83 |
|
Drugs Used in Pregnancy |
84 |
|
Fetal Therapeutics |
88 |
|
Maternal Therapeutics |
88 |
|
Drugs that Alter Uterine Motility: Tocolytics |
91 |
|
Drugs Used During Labor and Delivery
at Term |
93 |
|
Lactation |
95 |
|
The Nursing Process |
96 |
SECTION 3 |
DRUGS AFFECTING THE HEMATOPOIETIC AND IMMUNE SYSTEMS |
|
7 |
Drug Therapy for Coagulation Disorders |
101 |
|
Introduction |
102 |
|
Overview of Coagulation Disorders |
102 |
|
Anticoagulant Drugs |
104 |
|
Heparins |
104 |
|
Vitamin K Antagonists |
109 |
|
Direct Thrombin Inhibitors |
113 |
|
Antiplatelet Drugs |
114 |
|
Adenosine Diphosphate
Receptor Antagonists |
114 |
|
Other Antiplatelet
Drugs |
118 |
|
Thrombolytic Drugs |
119 |
|
Drugs Used to Control Bleeding |
123 |
|
The Nursing Process |
124 |
8 |
Drug Therapy for Dyslipidemia |
128 |
|
Introduction |
129 |
|
Overview of Dyslipidemia |
129 |
|
HMC-CoA Reductase Inhibitors |
133 |
|
Bile Acid Sequestrants |
137 |
|
Fibrates |
139 |
|
Cholesterol Absorption Inhibitor |
141 |
|
Miscellaneous Dyslipidemic
Agent |
142 |
|
Combination Therapy Used to Treat Dyslipidemia |
143 |
|
The Nursing Process |
144 |
9 |
Drug Therapy for Hematopoietic
Disorders and to Enhance Immunity |
147 |
|
Introduction |
148 |
|
Overview of Hematopoiesis
and Immune Function |
148 |
|
Erythrocyte Hematopoietic
Drugs |
151 |
|
Granulocyte Colony-Stimulating
Factors |
153 |
|
Interferons |
157 |
|
Adjuvant Medications Used to
Stimulate the Immune System: Interleukins |
159 |
|
The Nursing Process |
160 |
10 |
Drug Therapy: Immunizations |
162 |
|
Introduction |
163 |
|
Overview of Immunization |
163 |
|
Individual Immunizing Agents |
163 |
|
Keeping Up-to-Date with Immunization
Recommendations |
174 |
|
The Nursing Process |
175 |
11 |
Drug Therapy to Suppress Immunity |
178 |
|
Introduction |
179 |
|
Overview of Altered Immune Function |
179 |
|
Cytotoxic Immunosuppressive Agents |
182 |
|
Conventional Antirejection
Agents |
187 |
|
Adjuvant Medications Used to Suppress
Immune Function |
190 |
|
The Nursing Process |
194 |
12 |
Drug Therapy for the Treatment of Cancer |
197 |
|
Introduction |
198 |
|
Overview of Cancer |
198 |
|
Cytotoxic Antineoplastic
Drugs Used to Treat Cancer |
201 |
|
Adjuvant Medications Used to Treat
Cancer |
214 |
|
The Nursing Process |
222 |
SECTION 4 |
DRUGS AFFECTING INFLAMMATION AND INFECTION |
|
13 |
Inflammation, Infection, and the Use of Antimicrobial
Agents |
227 |
|
Introduction |
228 |
|
Overview of Inflammation |
228 |
|
Overview of Microorganisms |
230 |
|
The Nursing Process |
239 |
14 |
Drug Therapy to Decrease Pain, Fever, and Inflammation |
242 |
|
Introduction |
243 |
|
Overview of Pain, Fever, and
Inflammation |
245 |
|
Specific Conditions |
245 |
|
Salicylates |
248 |
|
Nonnarcotic Analgesic Antipyretic: Acetaminophen |
252 |
|
Nonsteroidal Anti-Inflammatory Drugs |
255 |
|
Selective COX-2 Inhibitor: Celecoxib |
262 |
|
Antigout Medication |
263 |
|
The Nursing Process |
267 |
15 |
Drug Therapy With Corticosteroids |
270 |
|
Introduction |
271 |
|
Physiology of Endogenous
Corticosteroids |
271 |
|
Pathophysiology of Adrenal Cortex Disorders |
273 |
|
Drug Therapy with Exogenous
Corticosteroids |
273 |
|
The Nursing Process |
287 |
16 |
Drug Therapy With Beta-Lactam
Antibacterial Agents |
291 |
|
Introduction |
292 |
|
Penicillins |
293 |
|
Cephalosporins |
298 |
|
Carbapenems |
305 |
|
Monobactams |
307 |
|
The Nursing Process |
309 |
17 |
Drug Therapy With Aminoglycosides
and Fluoroquinolones |
311 |
|
Introduction |
312 |
|
Aminoglycosides |
312 |
|
Fluoroquinolones |
316 |
|
The Nursing Process |
320 |
18 |
Drug Therapy With Tetracyclines,
Sulfonamides, and Urinary Antiseptics |
322 |
|
Introduction |
323 |
|
Tetracyclines |
323 |
|
Sulfonamides |
326 |
|
Adjuvant Medications Used to Treat
Urinary Tract Infections: Urinary Antiseptics |
330 |
|
The Nursing Process |
331 |
19 |
Drug Therapy With Macrolides, Ketolides, and Miscellaneous Anti-Infective Agents |
334 |
|
Introduction |
335 |
|
Macrolides |
335 |
|
Ketolides |
339 |
|
Miscellaneous Anti-Infective Agents |
341 |
|
The Nursing Process |
346 |
20 |
Drug Therapy for Tuberculosis and Mycobacterium avium
Complex Disease |
349 |
|
Introduction |
350 |
|
Overview of Tuberculosis and Mycobacterium avium Complex Disease |
350 |
|
Isoniazid |
354 |
|
Rifamycins |
357 |
|
Adjuvant First-Line Antitubercular Drugs |
360 |
|
First-Line Drug Combinations Used to Treat Tuberculosis |
362 |
|
Second-Line Drugs Used to Treat
Tuberculosis |
362 |
|
Drugs Used to Treat Mycobacterium avium
Complex Disease |
362 |
|
Special Strategies to Increase
Adherence to Antitubercular Drug Regimens |
362 |
|
The Nursing Process |
363 |
21 |
Drug Therapy for Viral Infections |
366 |
|
Introduction |
367 |
|
Overview of Viruses and Viral
Infections |
367 |
|
rugs for Herpesvirus
Infections |
370 |
|
rugs for Respiratory Syncytial Virus |
376 |
|
rugs for Influenza |
377 |
|
rugs for Hepatitis: Nucleoside
Analogs |
380 |
|
Drugs for Human Immunodeficiency
Virus Antiretroviral
Drugs) |
382 |
|
The Nursing Process |
394 |
22 |
Drug Therapy for Fungal Infections |
398 |
|
Introduction |
399 |
|
Overview of Fungal Infections |
399 |
|
Polyenes |
403 |
|
Azoles |
406 |
|
Echinocandins |
411 |
|
Miscellaneous Antifungal Agents for
Superficial Mycoses |
412 |
|
Pyrimidine Analog |
414 |
|
The Nursing Process |
416 |
23 |
Drug Therapy for Parasitic Infections |
419 |
|
Introduction |
420 |
|
Overview of Parasitic Infections |
420 |
|
Amebicides |
422 |
|
Antimalarials |
425 |
|
Anthelmintics |
428 |
|
Scabicldes and Pediculicides |
430 |
|
The Nursing Process |
431 |
SECTION 5 |
DRUGS AFFECTING THE CARDIOVASCULAR SYSTEM |
|
24 |
Drug Therapy for Heart Failure |
437 |
|
Introduction |
438 |
|
Overview of Heart Failure |
438 |
|
Inotropes (Cardiac Clycosides) |
441 |
|
Phosphodiesterase Inhibitors (Cardiotonic-Inotropic
Agents) |
447 |
|
Human B-Type Natriuretic
Peptides |
448 |
|
Adjuvant Medications Used to Treat
Heart Failure |
450 |
|
The Nursing Process |
452 |
25 |
Drug Therapy for Dysrhythmias |
456 |
|
Introduction |
457 |
|
Overview of Dysrhythmias |
457 |
|
Class I Sodium Channel Blockers |
460 |
|
Class II Beta-Adrenergic Blockers |
464 |
|
Class III Potassium Channel Blockers |
466 |
|
Class IV Calcium Channel Blockers |
469 |
|
Unclassified Antidysrhythmic
Drugs |
471 |
|
The Nursing Process |
471 |
26 |
Drug Therapy for Angina |
474 |
|
Introduction |
475 |
|
Overview of Angina |
476 |
|
Organic Nitrates |
477 |
|
Beta-Adrenergic Blockers |
483 |
|
Calcium Channel Blockers |
486 |
|
Adjuvant Medications |
489 |
|
The Nursing Process |
490 |
27 |
Drug Therapy to Enhance the Adrenergic Response |
493 |
|
Introduction |
494 |
|
Overview of the Adrenergic Response |
494 |
|
Adrenergic Drugs |
497 |
|
Toxicity of Adrenergics:
Recognition and Management |
505 |
|
The Nursing Process |
506 |
28 |
Drug Therapy for Hypertension |
510 |
|
Introduction |
511 |
|
Overview of Hypertension |
511 |
|
Angiotensin-Converting Enzyme Inhibitors |
515 |
|
Angiotensin II Receptor Blockers |
524 |
|
Adjuvant Medications Used to Treat Hypertension |
527 |
|
The Nursing Process |
533 |
SECTION 6 |
DRUGS AFFECTING THE RESPIRATORY SYSTEM |
|
29 |
Drug Therapy for Nasal Congestion |
539 |
|
Introduction |
540 |
|
Overview of Nasal Congestion and
Other Respiratory Symptoms |
540 |
|
Nasal Decongestants |
541 |
|
Antitussives |
545 |
|
Expectorants |
546 |
|
Mucolytics |
547 |
|
Herbal Preparations |
548 |
|
Combination Products |
548 |
|
The Nursing Process |
550 |
30 |
Drug Therapy to Decrease Histamine Effects and Allergic
Response |
553 |
|
Introduction |
554 |
|
Overview of Histamine Release and the Allergic
Response |
554 |
|
First-Generation H, Receptor
Antagonists |
558 |
|
Second-Generation H, Receptor
Antagonists |
563 |
|
The Nursing Process |
565 |
31 |
Drug Therapy for Asthma and Bronchoconstriction |
567 |
|
Introduction |
568 |
|
Overview of Asthma |
568 |
|
Adrenergics |
570 |
|
Anticholinergics |
576 |
|
Xanthines |
577 |
|
Corticosteroids |
580 |
|
Leukotriene Modifiers |
583 |
|
Adjuvant Medications Used to Treat
Asthma |
585 |
|
The Nursing Process |
586 |
SECTION 7 |
DRUGS AFFECTING THE RENAL AND DIGESTIVE SYSTEMS |
|
32 |
Drug Therapy for Fluid Volume Excess |
591 |
|
Introduction |
592 |
|
Renal Physiology |
592 |
|
Overview of Conditions Requiring
Diuretic Agents |
593 |
|
Thiazide Diuretics |
594 |
|
|
597 |
|
Potassium-Sparing Diuretics |
602 |
|
Adjuvant Medications Used to Treat
Fluid Volume Excess |
604 |
|
The Nursing Process |
605 |
33 |
Nutritional Support Products, Vitamins, and Mineral
Supplements |
608 |
|
Introduction |
609 |
|
Overview of Altered Nutritional
States |
609 |
|
Fat-Soluble Vitamins |
620 |
|
Water-Soluble Vitamins |
624 |
|
Minerals |
628 |
|
Treatment of Mineral Excess |
634 |
|
Nutritional Products |
635 |
|
The Nursing Process |
636 |
34 |
Drug Therapy for Weight Management |
640 |
|
Introduction |
641 |
|
Overview of Weight Management |
641 |
|
Adrenergic Anorexiants |
646 |
|
Lipase Inhibitors |
648 |
|
Other Drugs Used for Weight
Management |
650 |
|
Herbal and Dietary Supplements Used
for Weight Management |
650 |
|
The Nursing Process |
650 |
35 |
Drug Therapy for Peptic Ulcer Disease and Gastroesophageal Reflux Disease |
654 |
|
Introduction |
655 |
|
Overview of Peptic Ulcer Disease and Gastroesophageal Reflux Disease |
655 |
|
Antacids |
657 |
|
Histamine; Receptor Antagonists |
660 |
|
Proton Pump Inhibitors |
664 |
|
Adjuvant Medications Used to Treat
Peptic Ulcer Disease and Castroesophageal Reflux Disease |
667 |
|
The Nursing Process |
669 |
36 |
Drug Therapy for Nausea and Vomiting |
672 |
|
Introduction |
673 |
|
Overview of Nausea and Vomiting |
673 |
|
Phenothiazines |
674 |
|
Antihistamines |
677 |
|
5-Hydroxytryptamine3 (5-HT})
or Serotonin Receptor Antagonists |
679 |
|
Substance P/Neurokinin
1 Antagonist: Aprepitant |
681 |
|
Miscellaneous Antiemetics |
683 |
|
Nonpharmacologic Management |
684 |
|
The Nursing Process |
684 |
37 |
Drug Therapy for Constipation and Elimination Problems |
687 |
|
Introduction |
688 |
|
Overview of Constipation |
688 |
|
Laxatives |
690 |
|
Cathartics |
693 |
|
Miscellaneous Agents for Constipation |
696 |
|
The Nursing Process |
697 |
38 |
Drug Therapy for Diarrhea |
700 |
|
Introduction |
701 |
|
Overview of Diarrhea |
701 |
|
Opiate-Related Antidiarrheal
Agents |
702 |
|
Adjuvant Medications Used to Treat
Diarrhea |
706 |
|
The Nursing Process |
708 |
SECTION 8 |
DRUGS AFFECTING THE ENDOCRINE SYSTEM |
|
39 |
Drug Therapy for Diabetes Mellitus |
713 |
|
Introduction |
714 |
|
Overview of Diabetes |
714 |
|
Insulins |
718 |
|
Sulfonylureas |
730 |
|
Alpha-Clucosidase
Inhibitors |
733 |
|
Biguanides |
734 |
|
Thiazolidinediones |
735 |
|
Meglitinides |
737 |
|
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors |
739 |
|
Amylin Analogs |
740 |
|
Incretin Mimetics |
741 |
|
Adjuvant Medications Used to Treat
Diabetes |
742 |
|
The Nursing Process |
743 |
40 |
Drug Therapy for Hyperthyroidism and Hypothyroidism |
748 |
|
Introduction |
749 |
|
Overview of the Thyroid Gland |
749 |
|
Antithyroid Drugs |
752 |
|
Thyroid Drugs |
755 |
|
The Nursing Process |
759 |
41 |
Drug Therapy for Pituitary and Hypothalamic Dysfunction |
762 |
|
Introduction |
763 |
|
Overview of Pituitary and
Hypothalamic Dysfunction |
763 |
|
Anterior Pituitary Hormone Drugs for
Growth Deficiency
in Children |
766 |
|
Posterior Pituitary Hormone Drugs for
Diabetes Insipidus |
770 |
|
Hypothalamic Hormone Drugs |
772 |
|
The Nursing Process |
775 |
42 |
Drug Therapy to Regulate Calcium and Bone Metabolism |
778 |
|
Introduction |
779 |
|
Overview of Calcium and Bone
Metabolism |
780 |
|
Calcium Preparations |
783 |
|
Vitamin D |
787 |
|
Bisphosphonates |
788 |
|
Other Medications Used to Treat Bone
Disorders and Hypercalcemia |
790 |
|
The Nursing Process |
792 |
43 |
Drug Therapy for Addison’s Disease and Cushing’s Disease |
794 |
|
Introduction |
794 |
|
Overview of Addison’s Disease |
795 |
|
Overview of Cushing’s Disease |
796 |
|
Drugs Used to Treat Addison’s Disease |
797 |
|
Drugs Used to Treat Cushing’s Disease |
801 |
|
The Nursing Process |
803 |
SECTION 9 |
DRUGS AFFECTING WOMEN’S AND MEN’S HEALTH |
|
44 |
Drug Therapy for Women’s Health |
809 |
|
Introduction |
810 |
|
Overview of Reproduction in Women |
810 |
|
Estrogens |
812 |
|
Progestins |
818 |
|
Estrogen-Progestin Combinations |
821 |
|
The Nursing Process |
827 |
45 |
Drug Therapy for Men’s Health |
829 |
|
Introduction |
830 |
|
Overview of Reproductive Health
Problems in
Men |
830 |
|
Androgens and Anabolic Steroids |
833 |
|
Phosphodiesterase Type 5 Inhibitors |
836 |
|
Adjuvant Medications Used to Treat
Erectile Dysfunction |
838 |
|
Drugs for Benign Prostatic
Hypertrophy |
839 |
|
The Nursing Process |
842 |
SECTION 10 |
DRUGS AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM |
|
46 |
Drug Therapy for Myasthenia Gravis and Alzheimer’s
Disease |
847 |
|
Introduction |
848 |
|
Overview of Myasthenia Gravis |
848 |
|
Indirect-Acting Cholinergics |
849 |
|
Overview of Alzheimer’s Disease |
853 |
|
Reversible Indirect-Acting Cholinergics |
853 |
|
Overview of Urinary Retention |
856 |
|
Direct-Acting Cholinergics |
856 |
|
Irreversible Anticholinesterase
Toxicity |
857 |
|
The Nursing Process |
858 |
47 |
Drug Therapy for Parkinson’s Disease and Anticholinergics |
862 |
|
Overview of Parkinson’s Disease |
863 |
|
Dopamine Receptor Agonists |
864 |
|
Catechol-O-Methyltransferase Inhibitors |
870 |
|
Catechol-O-Methyltransferase Inhibitor and Decarboxylase
Inhibitor/Dopamine Precursor |
872 |
|
The Nursing Process |
874 |
|
Overview of Anticholinergic
Drugs |
874 |
|
Belladonna Alkaloid and Derivatives |
876 |
|
Centrally Acting Anticholinergics |
880 |
|
Gastrointestinal Anticholinergics
(Antisecretory/ Antispasmodic) |
882 |
|
Urinary Antispasmodics |
883 |
|
The Nursing Process |
885 |
48 |
Drug Therapy With Opioids |
888 |
|
Introduction |
889 |
|
Overview of Pain |
889 |
|
Opioid Agonists |
891 |
|
Opioid Agonists/Antagonists |
900 |
|
Opioid Antagonists |
902 |
|
The Nursing Process |
904 |
49 |
Drug Therapy With Local Anesthetics |
907 |
|
Introduction |
908 |
|
Overview of Local Anesthesia |
908 |
|
Amides |
908 |
|
Esters |
912 |
|
The Nursing Process |
913 |
50 |
Drug Therapy With General Anesthetics |
915 |
|
Introduction |
916 |
|
Overview of General Anesthesia |
916 |
|
Inhalation Anesthetics |
917 |
|
Intravenous Anesthetics |
920 |
|
Neuromuscular Blocking Agents |
923 |
|
Adjuvant Medications Used in General Anesthesia |
927 |
|
The Nursing Process |
927 |
51 |
Drug Therapy for Migraines and Other Headaches |
932 |
|
Introduction |
933 |
|
Overview of Migraine Headaches |
933 |
|
Nonsteroidal Anti-Inflammatory Agents |
935 |
|
Acetaminophen, Aspirin, and Caffeine |
936 |
|
Ergot Alkaloids |
938 |
|
Triptans |
940 |
|
Estrogen |
943 |
|
Preventive Therapy for Migraine
Headaches |
943 |
|
Adjuvant Medications for Migraine
Headaches |
945 |
|
The Nursing Process |
946 |
52 |
Drug Therapy for Seizure Disorders and Spasticity |
949 |
|
Introduction |
950 |
|
Overview of Epilepsy |
950 |
|
Drugs Used to Treat Seizure Disorders |
952 |
|
Other Antiepileptic Drugs |
964 |
|
The Nursing Process |
972 |
|
Overview of Spinal Cord Injury |
973 |
|
Drugs Used to Treat Muscle Spasms and Spasticity |
974 |
|
The Nursing Process |
980 |
53 |
Drug Therapy to Reduce Anxiety and Produce Hypnosis |
983 |
|
Introduction |
984 |
|
Overview of Anxiety |
984 |
|
Overview of Sleep and Insomnia |
986 |
|
Benzodiazepines |
988 |
|
Nonbenzodiazepine Sedative-Hypnotic Agents |
993 |
|
The Nursing Process |
996 |
54 |
Drug Therapy for Depression and Mood Stabilization |
1000 |
|
Introduction |
1001 |
|
Overview of Depression |
1001 |
|
Overview of Bipolar Disorder |
1004 |
|
Tricyclic Antidepressants |
1004 |
|
Selective Serotonin Reuptake
inhibitors |
1008 |
|
Serotonin-Norepinephrine
Reuptake Inhibitors |
1011 |
|
Monoamine Oxidase
Inhibitors |
1012 |
|
Atypical Antidepressants |
1014 |
|
Mood-Stabilizing Agents: Drugs Used
to Treat Bipolar Disorder |
1015 |
|
Other Medications Used to Treat
Bipolar Disorder |
1018 |
|
The Nursing Process |
1018 |
55 |
Drug Therapy for Psychotic Disorders |
1022 |
|
Introduction |
1023 |
|
Overview of Psychosis |
1023 |
|
Phenothiazine Antipsychotics |
1026 |
|
Nonphenothiazines |
1029 |
|
The Nursing Process |
1036 |
56 |
Drug Therapy to Stimulate the Central Nervous System |
1040 |
|
Introduction |
1041 |
|
Overview of Attention Deficit
Hyperactivity Disorder |
1041 |
|
Overview of Narcolepsy |
1042 |
|
Stimulants |
1042 |
|
Other Medications Used to Treat
Attention Deficit Hyperactivity Disorder and Narcolepsy |
1051 |
|
Herbal and Dietary Supplements |
1051 |
|
The Nursing Process |
1052 |
57 |
Drug Therapy for Substance Abuse Disorders |
1055 |
|
Introduction |
1056 |
|
Overview of Substance Abuse and
Dependence |
1056 |
|
Central Nervous System Depressant
Abuse and Dependence:
Drug Therapy |
1059 |
|
Central Nervous System Stimulant
Abuse and Dependence:
Drug Therapy |
1064 |
|
Psychoactive Substance Abuse and
Dependence: Drug
Therapy |
1065 |
|
The Nursing Process |
1067 |
SECTION 11 |
DRUGS AFFECTING THE EYE, EAR, AND SKIN |
|
58 |
Drug Therapy for Disorders of the Eye |
1073 |
|
Introduction |
1074 |
|
Basic Structure and Function of the
Eye |
1074 |
|
Overview of Disorders of the Eye |
1074 |
|
Drug Therapy for the Diagnosis and
Treatment of Ocular Disorders |
1076 |
|
Drug Therapy for the Treatment of
Glaucoma |
1080 |
|
Drug Therapy for Ocular Infections
and Inflammation |
1088 |
|
The Nursing Process |
1095 |
59 |
Drug Therapy for Disorders of the Ear |
1098 |
|
Introduction |
1099 |
|
Overview of Disorders of the Ear |
1099 |
|
Anti-Infective, Antiseptic, Clucocorticoid, and Acidifying Agents |
1100 |
|
Fluoroquinolone: Ciprofloxacin |
1102 |
|
Penicillin: Amoxicillin |
1104 |
|
Adjuvant Medications to Treat Pain
and Fever Related to Infections of the Ear |
1105 |
|
The Nursing Process |
1105 |
60 |
Drug Therapy for Disorders of the Skin |
1108 |
|
Introduction |
1109 |
|
Disorders of the Skin |
1109 |
|
Drug Therapy |
1111 |
|
Retinoids |
1116 |
|
The Nursing Process |
1118 |
|
Index |
|
|
AVAILABLE ON thePoint |
|
Appendix A |
Answers for NCLEX Success |
|
Appendix B |
Answers for the Clinical Application Case Studies |
|
Appendix C |
Answers for the Critical Thinking Questions |
|
Appendix D |
The International System of Units |
|
Appendix E |
Serum Drug Concentrations |
|
|
|
|